Vir Biotechnology Shares Jump on Gilead Cancer Collaboration
By Adriano Marchese
Vir Biotechnology shares jumped Wednesday morning after the company said it signed an agreement with Gilead Sciences to discover and develop next-generation t-cell engagers for solid tumors.
Shares traded 8.2% at $11.48 ahead of the morning bell.
The clinical-stage biopharmaceutical company has signed a collaboration and license agreement with Gilead to discover and engineer three novel dual-masked T-cell engager development candidates aimed at targeting solid tumor-associated antigens.
T-cell engagers, or TCEs, are powerful anti-tumor agents designed to direct the immune system, specifically T-cells, to destroy cancer cells. TCEs have become an important treatment option for blood cancers, but their usage in solid tumors has been limited due to toxicity.
Gilead will have an exclusive license to nominate and advance candidates developed under the collaboration and will be responsible for development, manufacturing and commercialization activities.
As part of the deal, Vir will be in line to receive a total of $135 million in payments, made up of a $65 million cash portion and a $25 million equity investment at a 30% premium, as well as up to $45 million in potential near-term preclinical milestones.
Vir added that it has the potential to receive up to $1.74 billion in further development, regulatory and commercial milestones, along with tiered high single-digit to low double-digit royalties on net sales.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 14, 2026 09:59 ET (13:59 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States